Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Tablet, Oral, 25 mg, Once daily (QD), 12 weeks

Tablet, Oral, 50 mg, Once daily (QD), 12 weeks

Tablet, Oral, 100 mg, Once daily (QD), 12 weeks

Tablet, Oral, 0 mg, Once daily (QD), 12 weeks

Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks

Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Tablet, Oral, 200 mg, QD, 12 weeks

Tablet, Oral, 60 mg, QD, 12 weeks